| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Oliver Freudenreich, David C Henderson, Eric A Macklin, A Eden Evins, Xiaoduo Fan, Cori Cather, Jared P Walsh, Donald C Gof. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. The Journal of clinical psychiatry. vol 70. issue 12. 2010-02-23. PMID:19689921. |
patients with schizophrenia often suffer from cognitive deficits and negative symptoms that are poorly responsive to antipsychotics including clozapine. |
2010-02-23 |
2023-08-12 |
Not clear |
| Renan P Souza, Maria Tampakeras, Vince Basile, Takahiro Shinkai, Daniela V F Rosa, Steve Potkin, Herbert Y Meltzer, Jeffrey A Lieberman, Marco A Romano-Silva, James L Kenned. Lack of association of GPX1 and MnSOD genes with symptom severity and response to clozapine treatment in schizophrenia subjects. Human psychopharmacology. vol 24. issue 8. 2010-02-18. PMID:19946932. |
lack of association of gpx1 and mnsod genes with symptom severity and response to clozapine treatment in schizophrenia subjects. |
2010-02-18 |
2023-08-12 |
human |
| Shikma Keller, Heinz Drexler, Pesach Lichtenber. Very high-dose clozapine and electroconvulsive therapy combination treatment in a patient with schizophrenia. The journal of ECT. vol 25. issue 4. 2010-02-17. PMID:19440159. |
very high-dose clozapine and electroconvulsive therapy combination treatment in a patient with schizophrenia. |
2010-02-17 |
2023-08-12 |
Not clear |
| Shikma Keller, Heinz Drexler, Pesach Lichtenber. Very high-dose clozapine and electroconvulsive therapy combination treatment in a patient with schizophrenia. The journal of ECT. vol 25. issue 4. 2010-02-17. PMID:19440159. |
we report here the case of a 19-year-old man with paranoid schizophrenia who responded only partially to treatment with daily doses of clozapine, 1800 mg; aripiprazole, 20 mg; and clonazepam, 6 mg. we reduced the clozapine to 1600 to 1700 mg, maintaining therapeutic serum levels, and added a course of electroconvulsive therapy that included 24 treatments. |
2010-02-17 |
2023-08-12 |
Not clear |
| Avril Pereira, George Fink, Suresh Sundra. Clozapine-induced ERK1 and ERK2 signaling in prefrontal cortex is mediated by the EGF receptor. Journal of molecular neuroscience : MN. vol 39. issue 1-2. 2010-02-12. PMID:19277491. |
the atypical antipsychotic drug clozapine is effective in treatment-refractory schizophrenia. |
2010-02-12 |
2023-08-12 |
mouse |
| Gijsbert J de Bruin, Dirk J Bac, Eugène P van Puijenbroek, Johan M van der Klooste. [Ogilvie Syndrome induced by clozapine]. Nederlands tijdschrift voor geneeskunde. vol 153. 2010-02-01. PMID:20051163. |
clozapine is an antipsychotic drug which is used in the treatment of therapy-resistant schizophrenia. |
2010-02-01 |
2023-08-12 |
Not clear |
| Gijsbert J de Bruin, Dirk J Bac, Eugène P van Puijenbroek, Johan M van der Klooste. [Ogilvie Syndrome induced by clozapine]. Nederlands tijdschrift voor geneeskunde. vol 153. 2010-02-01. PMID:20051163. |
here we describe the case of a 28-year-old man with schizophrenia who developed constipation and abdominal distension for several weeks while taking clozapine. |
2010-02-01 |
2023-08-12 |
Not clear |
| David C Henderson, Xiaoduo Fan, Bikash Sharma, Paul M Copeland, Christina P C Borba, Oliver Freudenreich, Corinne Cather, A Eden Evins, Donald C Gof. Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine. Journal of psychiatric practice. vol 15. issue 4. 2010-01-29. PMID:19625881. |
waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine. |
2010-01-29 |
2023-08-12 |
human |
| David C Henderson, Xiaoduo Fan, Bikash Sharma, Paul M Copeland, Christina P C Borba, Oliver Freudenreich, Corinne Cather, A Eden Evins, Donald C Gof. Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine. Journal of psychiatric practice. vol 15. issue 4. 2010-01-29. PMID:19625881. |
the goal of this study was to evaluate which anthropometric measure (human body measurement) best predicts insulin resistance measured by the insulin sensitivity index (si) and the homeostasis model of assessment of insulin resistance (homa-ir) in nondiabetic patients with schizophrenia treated with clozapine or olanzapine. |
2010-01-29 |
2023-08-12 |
human |
| Bart Peters, Lieuwe de Haa. Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole. Progress in neuro-psychopharmacology & biological psychiatry. vol 33. issue 8. 2010-01-25. PMID:19766686. |
remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole. |
2010-01-25 |
2023-08-12 |
Not clear |
| Eva María Sánchez-Morla, José Luis Santos, Ana Aparicio, María Angeles García-Jiménez, Clara Villanueva, Vicente Martínez-Vizcaíno, Celso Arang. Antipsychotic effects on auditory sensory gating in schizophrenia patients. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 19. issue 12. 2010-01-25. PMID:19833483. |
the current study was designed to determine whether there is a difference in p50 gating in schizophrenia patients treated with first-generation antipsychotics (fgas) and second-generation antipsychotics (sgas), including clozapine. |
2010-01-25 |
2023-08-12 |
human |
| Kathleen S Alexander, Julie M Brooks, Martin Sarter, John P Brun. Disruption of mesolimbic regulation of prefrontal cholinergic transmission in an animal model of schizophrenia and normalization by chronic clozapine treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 34. issue 13. 2010-01-19. PMID:19693002. |
disruption of mesolimbic regulation of prefrontal cholinergic transmission in an animal model of schizophrenia and normalization by chronic clozapine treatment. |
2010-01-19 |
2023-08-12 |
rat |
| Kathleen S Alexander, Julie M Brooks, Martin Sarter, John P Brun. Disruption of mesolimbic regulation of prefrontal cholinergic transmission in an animal model of schizophrenia and normalization by chronic clozapine treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 34. issue 13. 2010-01-19. PMID:19693002. |
these experiments show that mesolimbic regulation of cortical ach release is disrupted in postpubertal nvhlx rats and normalized by low-dose treatment of clozapine; supporting the usefulness of nvhlx animals for research on the neuronal mechanisms underlying the cognitive symptoms of schizophrenia. |
2010-01-19 |
2023-08-12 |
rat |
| Yael Piontkewitz, Yaniv Assaf, Ina Weine. Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia. Biological psychiatry. vol 66. issue 11. 2010-01-15. PMID:19726031. |
clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia. |
2010-01-15 |
2023-08-12 |
Not clear |
| Yael Piontkewitz, Yaniv Assaf, Ina Weine. Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia. Biological psychiatry. vol 66. issue 11. 2010-01-15. PMID:19726031. |
we used a neurodevelopmental animal model of schizophrenia to assess the efficacy of the atypical antipsychotic clozapine to prevent neuroanatomical deterioration. |
2010-01-15 |
2023-08-12 |
Not clear |
| A Wheeler, V Humberstone, G Robinso. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? Journal of psychopharmacology (Oxford, England). vol 23. issue 8. 2010-01-12. PMID:18635713. |
outcomes for schizophrenia patients with clozapine treatment: how good does it get? |
2010-01-12 |
2023-08-12 |
Not clear |
| A Wheeler, V Humberstone, G Robinso. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? Journal of psychopharmacology (Oxford, England). vol 23. issue 8. 2010-01-12. PMID:18635713. |
the objective of this study was to describe the extent/change (2000-2004) of clozapine prescribing in schizophrenia in new zealand and examine the outcomes associated with increasing treatment duration, and vs. those who discontinue clozapine. |
2010-01-12 |
2023-08-12 |
Not clear |
| A Wheeler, V Humberstone, G Robinso. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? Journal of psychopharmacology (Oxford, England). vol 23. issue 8. 2010-01-12. PMID:18635713. |
between 2000 and 2004, clozapine for schizophrenia increased from 21.0% to 32.8%. |
2010-01-12 |
2023-08-12 |
Not clear |
| A Wheeler, V Humberstone, G Robinso. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? Journal of psychopharmacology (Oxford, England). vol 23. issue 8. 2010-01-12. PMID:18635713. |
clozapine use increased significantly over 4.5 years to expected rates of treatment-resistant schizophrenia. |
2010-01-12 |
2023-08-12 |
Not clear |
| A Wheeler, V Humberstone, G Robinso. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? Journal of psychopharmacology (Oxford, England). vol 23. issue 8. 2010-01-12. PMID:18635713. |
these findings support the recommendation of prolonged clozapine trials to improve cost-effectiveness in the most seriously unwell schizophrenia patients. |
2010-01-12 |
2023-08-12 |
Not clear |